The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.
NeoGenomics' clinical genetic testing revenues were up 7 percent year over year, as the number of genetic tests completed increased by 16 percent.
The Index gained 2 percent in June, outperforming the Dow and the Nasdaq, but underperforming the Nasdaq Biotechnology Index, which gained nearly 9 percent.
The firm guided second quarter revenues to between $62 million and $64 million and revised its full-year 2017 revenue guidance to between $255 million and $265 million.
The companies have expanded their relationship to include the development and automation of assays for clinical trials and clinical testing.
The company issued preliminary guidance for 2017 of $260 million to $275 million in revenues and adjusted EPS of between $.17 and $.22.
The company lowered its financial guidance for fiscal 2016, citing delays in recognizing fourth quarter revenue from its pharma services business.
The revenue growth was driven by clinical genetic testing volume, which benefitted from the inclusion of the 2015 acquisition of Clarient.
The investment bank said NeoGenomics and its clients are likely to benefit from a product portfolio expanded by the acquisition of Clarient.
The company's Q2 net loss attributable to common stockholders widened to $5.2 million from essentially break even a year ago.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.